Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients

References

• Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142–1147.
   PubMed Web of Science ®Google Scholar
• McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. Circulation. 2012;126:e143–146.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–e76.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Hammill BG, Sinner MF, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993–2007. Circ Cardiovasc Qual Outcomes. 2012;5:85–93.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Public health and aging: trends in aging – United States and worldwide. JAMA. 2003;289:1371–1373.
   PubMed Web of Science ®Google Scholar
• Delaney JAC, Yin X, Fontes JD, et al. Hospital and clinical care costs associated with atrial fibrillation for Medicare beneficiaries in the Cardiovascular Health Study and the Framingham Heart Study. SAGE Open Med. 2018;6:2050312118759444.
   Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–982.
   PubMed Web of Science ®Google Scholar
• Diez-Villanueva P, Alfonso F. Atrial fibrillation in the elderly. J Geriatr Cardiol. 2019;16:49–53.
   PubMedGoogle Scholar
• Rutherford OW, Jonasson C, Ghanima W, et al. New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs. Open Heart. 2018;5:e000931.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Farmer C, Luo C, et al. Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. Curr Med Res Opin. 2018;34:487–498.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Luo X, Gupta K, et al. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2017;33:1745–1754.
   PubMed Web of Science ®Google Scholar
• Levin P, Wei W, Miao R, et al. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data. Diabetes Obes Metab. 2015;17:245–253.
   PubMed Web of Science ®Google Scholar
• Xie L, Zhou S, Wei W, et al. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus. Diabetes Tech Ther. 2013;15:230–236.
   PubMed Web of Science ®Google Scholar
• Baker CL, Dhamane AD, Rajpura J, et al. Hospitalization outcomes for patients with nonvalvular atrial fibrillation who continue apixaban treatment compared to patients who switch to another oral anticoagulant. Manuscript submitted. Adv Ther.
   Google Scholar
• Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:e003725.
   PubMed Web of Science ®Google Scholar
• Lip GY, Pan X, Kamble S, et al. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in the United States. Int J Clin Pract. 2016;70:752–763.
   PubMed Web of Science ®Google Scholar
• Li XS, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017;117:1072–1082.
   PubMed Web of Science ®Google Scholar
• Li X, Keshishian A, Hamilton M, et al. Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using a propensity-score-matched approach. PLoS One. 2018;13:e0191722.
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Coupland C, Hill T, et al. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362:k2505.
   PubMed Web of Science ®Google Scholar
• Lin J, Trocio J, Gupta K, et al. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting. J Med Econ. 2017;20:952–961.
   PubMed Web of Science ®Google Scholar
• Amin A, Keshishian A, Trocio J, et al. A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the U.S. Medicare population. JMCP. 2018;24:911–920.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Luo X, Gupta K, et al. Effect of apixaban versus warfarin use on health care resource utilization and costs among elderly patients with nonvalvular atrial fibrillation. JMCP. 2017;11:1191–1201.
   Google Scholar
• Li G, Lip GYH, Holbrook H, et al. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol. 2019;34:173–190.
   PubMed Web of Science ®Google Scholar
• Tepper PG, Mardekian J, Masseria C, et al. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. PLoS One. 2018;13:e0205989.
   PubMed Web of Science ®Google Scholar
• Noseworthy PA, Yao X, Abraham NS, et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest. 2016;150:1302–1312.
   PubMed Web of Science ®Google Scholar
• Gupta K, Trocio J, Keshishian A, et al. Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the U.S. Department of Defense population. JMCP. 2018;11:1116–1127.
   Google Scholar